Swansea AGPU-Which Anticoagulant VTE

Swansea AGPU-Which Anticoagulant VTE

<p> Swansea AGPU-which anticoagulant VTE?</p><p>Which anticoagulant to prescribe:</p><p>Use antithrombotic agents with caution in patient with an increased bleeding risk such as;</p><p> o Thrombocytopenia, if <100 not suitable for outpatient management</p><p> o Recent cerebral haemorrhage or CNS surgery within 12 weeks</p><p> o Uncontrolled hypertension (sustained readings of systolic >200mmHg, diastolic 110mmHg)</p><p> o Lesions liable to substantial haemorrhage e.g. varices, active peptic ulceration, bleeding haemorrhoids</p><p>RIVAROXABAN (XARELTO) ENOXAPARIN (CLEXANE) WARFARIN</p><p>INCLUSION INCLUSION INCLUSION o Patients confirmed as having a 1st DVT o Active treatment for o All patients who are o Vulnerable e.g. dementia, confusion, cancer excluded from taking learning difficulties, where having daily o Solid tumour cancers Rivaroxaban injections and blood tests may be o Intravenous drug o Patients requiring detrimental to the patient’s health and users or suspected lifelong anticoagulation well being alcohol misuse as for recurrent VTE o Needle phobic there is an increased (whilst Rivaroxaban o Dependant on WAST ambulance risk of non-compliance cannot be prescribed in transport to attend the hospital o Strong possibility for Primary Care in o Dependant on public transport to non-compliance Swansea/NPT) attend and has to take ≥3 buses/trains o Enoxaparin or Warfarin Contraindicated EXCLUSION EXCLUSION o Known o Pregnancy EXCLUSION hypersensitivity to o Active treatment for o Age ≤ 17 years heparin or excipients cancer o Active cancer o Patient on o Solid tumour cancers o Pregnancy and breast feeding Rivaroxaban o Intravenous drug users o Creatinine Clearance <15ml/min or suspected alcohol o Clinically significant active bleeding misuse as there is an o Hepatic disease associated with increased risk of non- coagulopathy and clinically relevant compliance bleeding risk including cirrhotic o Strong possibility for patients with Child Pugh B & C non-compliance o With systemic azole-antimycotics e.g. o Known hypersensitivity ketoconazole, itraconazole, to heparin or excipients voriconazole and posaconazole o HIV protease inhibitors e.g. ritonavir o Known hypersensitivity to Rivaroxaban or excipients o Patient already prescribed Warfarin for other indication o Concomitant use with Enoxaparin/Warfarin o Recurrent DVT (whilst prescribing cannot be done in Primary Care in Swansea/NPT)</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us